Isavuconazole for COVID-19-Associated Invasive Mold Infections
Open Access
- 28 June 2022
- journal article
- review article
- Published by MDPI AG in Journal of Fungi
- Vol. 8 (7), 674
- https://doi.org/10.3390/jof8070674
Abstract
Isavuconazole is a broad-spectrum antifungal drug recently approved as a first-line treatment for invasive aspergillosis and as a first or alternative treatment for mucormycosis. The purpose of this review was to report and discuss the use of isavuconazole for the treatment of COVID-19-associated aspergillosis (CAPA), and COVID-19-associated mucormycosis (CAM). Among all studies which reported treatment of CAPA, approximately 10% of patients were reportedly treated with isavuconazole. Considering 14 identified studies that reported the use of isavuconazole for CAPA, isavuconazole was used in 40% of patients (95 of 235 treated patients), being first-line monotherapy in over half of them. We identified six studies that reported isavuconazole use in CAM, either alone or in combination therapy. Overall, isavuconazole was used as therapy in 13% of treated CAM patients, frequently as combination or sequential therapy. The use of isavuconazole in CAPA and CAM is complicated by the challenge of achieving adequate exposure in COVID-19 patients who are frequently obese and hospitalized in the ICU with concomitant renal replacement therapy (RRT) or extracorporeal membrane oxygenation (ECMO). The presence of data on high efficacy in the treatment of aspergillosis, lower potential for drug–drug interactions (DDIs) and for subtherapeutic levels, and no risk of QT prolongation compared to other mold-active azoles, better safety profile than voriconazole, and the possibility of using an intravenous formulation in the case of renal failure are the advantages of using isavuconazole in this setting.Keywords
This publication has 89 references indexed in Scilit:
- Population Pharmacokinetics of Isavuconazole in Subjects with Mild or Moderate Hepatic ImpairmentAntimicrobial Agents and Chemotherapy, 2016
- Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysisThe Lancet Infectious Diseases, 2016
- Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trialThe Lancet, 2015
- In Vitro Activity of Isavuconazole and Comparators against Clinical Isolates of the Mucorales OrderAntimicrobial Agents and Chemotherapy, 2015
- Prospective Multicenter International Surveillance of Azole Resistance inAspergillus fumigatusEmerging Infectious Diseases, 2015
- Safety and Pharmacokinetics of Isavuconazole as Antifungal Prophylaxis in Acute Myeloid Leukemia Patients with Neutropenia: Results of a Phase 2, Dose Escalation StudyAntimicrobial Agents and Chemotherapy, 2015
- In Vitro Antifungal Activity of Isavuconazole against Madurella mycetomatisAntimicrobial Agents and Chemotherapy, 2012
- Effect of Mild and Moderate Liver Disease on the Pharmacokinetics of Isavuconazole after Intravenous and Oral Administration of a Single Dose of the Prodrug BAL8557Antimicrobial Agents and Chemotherapy, 2009
- Multiple-Dose Pharmacokinetics and Safety of the New Antifungal Triazole BAL4815 after Intravenous Infusion and Oral Administration of Its Prodrug, BAL8557, in Healthy VolunteersAntimicrobial Agents and Chemotherapy, 2006
- Single-Ascending-Dose Pharmacokinetics and Safety of the Novel Broad-Spectrum Antifungal Triazole BAL4815 after Intravenous Infusions (50, 100, and 200 Milligrams) and Oral Administrations (100, 200, and 400 Milligrams) of Its Prodrug, BAL8557, in Healthy VolunteersAntimicrobial Agents and Chemotherapy, 2006